Helicobacter pylori Antibody Titer and Gastric Cancer Screening

The “ABC method” is a serum gastric cancer screening method, and the subjects were divided based on H. pylori serology and atrophic gastritis as detected by serum pepsinogen (PG): Group A [H. pylori (−) PG (−)], Group B [H. pylori (+) PG (−)], Group C [H. pylori (+) PG (+)], and Group D [H. pylori (...

Full description

Bibliographic Details
Main Authors: Hiroshi Kishikawa, Kayoko Kimura, Sakiko Takarabe, Shogo Kaida, Jiro Nishida
Format: Article
Language:English
Published: Hindawi Limited 2015-01-01
Series:Disease Markers
Online Access:http://dx.doi.org/10.1155/2015/156719
id doaj-24b894a355d5498eb879920c4c3c9c2b
record_format Article
spelling doaj-24b894a355d5498eb879920c4c3c9c2b2020-11-24T20:53:18ZengHindawi LimitedDisease Markers0278-02401875-86302015-01-01201510.1155/2015/156719156719Helicobacter pylori Antibody Titer and Gastric Cancer ScreeningHiroshi Kishikawa0Kayoko Kimura1Sakiko Takarabe2Shogo Kaida3Jiro Nishida4Department of Gastroenterology, Tokyo Dental College, Ichikawa General Hospital, 5-11-13 Sugano, Ichikawa, Chiba 272-8513, JapanDepartment of Gastroenterology, Tokyo Dental College, Ichikawa General Hospital, 5-11-13 Sugano, Ichikawa, Chiba 272-8513, JapanDepartment of Gastroenterology, Tokyo Dental College, Ichikawa General Hospital, 5-11-13 Sugano, Ichikawa, Chiba 272-8513, JapanDepartment of Gastroenterology, Tokyo Dental College, Ichikawa General Hospital, 5-11-13 Sugano, Ichikawa, Chiba 272-8513, JapanDepartment of Gastroenterology, Tokyo Dental College, Ichikawa General Hospital, 5-11-13 Sugano, Ichikawa, Chiba 272-8513, JapanThe “ABC method” is a serum gastric cancer screening method, and the subjects were divided based on H. pylori serology and atrophic gastritis as detected by serum pepsinogen (PG): Group A [H. pylori (−) PG (−)], Group B [H. pylori (+) PG (−)], Group C [H. pylori (+) PG (+)], and Group D [H. pylori (−) PG (+)]. The risk of gastric cancer is highest in Group D, followed by Groups C, B, and A. Groups B, C, and D are advised to undergo endoscopy, and the recommended surveillance is every three years, every two years, and annually, respectively. In this report, the reported results with respect to further risk stratification by anti-H. pylori antibody titer in each subgroup are reviewed: (1) high-negative antibody titer subjects in Group A, representing posteradicated individuals with high risk for intestinal-type cancer; (2) high-positive antibody titer subjects in Group B, representing active inflammation with high risk for diffuse-type cancer; and (3) low-positive antibody titer subjects in Group C, representing advanced atrophy with increased risk for intestinal-type cancer. In these subjects, careful follow-up with intervals of surveillance of every three years in (1), every two years in (2), and annually in (3) should be considered.http://dx.doi.org/10.1155/2015/156719
collection DOAJ
language English
format Article
sources DOAJ
author Hiroshi Kishikawa
Kayoko Kimura
Sakiko Takarabe
Shogo Kaida
Jiro Nishida
spellingShingle Hiroshi Kishikawa
Kayoko Kimura
Sakiko Takarabe
Shogo Kaida
Jiro Nishida
Helicobacter pylori Antibody Titer and Gastric Cancer Screening
Disease Markers
author_facet Hiroshi Kishikawa
Kayoko Kimura
Sakiko Takarabe
Shogo Kaida
Jiro Nishida
author_sort Hiroshi Kishikawa
title Helicobacter pylori Antibody Titer and Gastric Cancer Screening
title_short Helicobacter pylori Antibody Titer and Gastric Cancer Screening
title_full Helicobacter pylori Antibody Titer and Gastric Cancer Screening
title_fullStr Helicobacter pylori Antibody Titer and Gastric Cancer Screening
title_full_unstemmed Helicobacter pylori Antibody Titer and Gastric Cancer Screening
title_sort helicobacter pylori antibody titer and gastric cancer screening
publisher Hindawi Limited
series Disease Markers
issn 0278-0240
1875-8630
publishDate 2015-01-01
description The “ABC method” is a serum gastric cancer screening method, and the subjects were divided based on H. pylori serology and atrophic gastritis as detected by serum pepsinogen (PG): Group A [H. pylori (−) PG (−)], Group B [H. pylori (+) PG (−)], Group C [H. pylori (+) PG (+)], and Group D [H. pylori (−) PG (+)]. The risk of gastric cancer is highest in Group D, followed by Groups C, B, and A. Groups B, C, and D are advised to undergo endoscopy, and the recommended surveillance is every three years, every two years, and annually, respectively. In this report, the reported results with respect to further risk stratification by anti-H. pylori antibody titer in each subgroup are reviewed: (1) high-negative antibody titer subjects in Group A, representing posteradicated individuals with high risk for intestinal-type cancer; (2) high-positive antibody titer subjects in Group B, representing active inflammation with high risk for diffuse-type cancer; and (3) low-positive antibody titer subjects in Group C, representing advanced atrophy with increased risk for intestinal-type cancer. In these subjects, careful follow-up with intervals of surveillance of every three years in (1), every two years in (2), and annually in (3) should be considered.
url http://dx.doi.org/10.1155/2015/156719
work_keys_str_mv AT hiroshikishikawa helicobacterpyloriantibodytiterandgastriccancerscreening
AT kayokokimura helicobacterpyloriantibodytiterandgastriccancerscreening
AT sakikotakarabe helicobacterpyloriantibodytiterandgastriccancerscreening
AT shogokaida helicobacterpyloriantibodytiterandgastriccancerscreening
AT jironishida helicobacterpyloriantibodytiterandgastriccancerscreening
_version_ 1716797498915291136